2.61
price down icon16.35%   -0.51
after-market アフターアワーズ: 2.61
loading
前日終値:
$3.12
開ける:
$3.07
24時間の取引高:
40,554
Relative Volume:
5.67
時価総額:
$5.21M
収益:
$2.54M
当期純損益:
$-4.13M
株価収益率:
-0.9491
EPS:
-2.75
ネットキャッシュフロー:
$-4.11M
1週間 パフォーマンス:
-22.78%
1か月 パフォーマンス:
-33.42%
6か月 パフォーマンス:
-39.58%
1年 パフォーマンス:
-30.77%
1日の値動き範囲:
Value
$2.5005
$3.12
1週間の範囲:
Value
$2.5005
$3.43
52週間の値動き範囲:
Value
$2.5005
$5.20

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name
名前
Xenetic Biosciences Inc
Name
セクター
Healthcare (1164)
Name
電話
781-778-7720
Name
住所
945 CONCORD ST., FRAMINGHAM, MA
Name
職員
0
Name
Twitter
@XeneticBio
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
XBIO's Discussions on Twitter

XBIO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
XBIO
Xenetic Biosciences Inc
2.61 5.21M 2.54M -4.13M -4.11M -2.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2020-01-08 開始されました Maxim Group Buy

Xenetic Biosciences Inc (XBIO) 最新ニュース

pulisher
12:53 PM

Xenetic Biosciences stock hits 52-week low at $2.7 - Investing.com

12:53 PM
pulisher
Mar 28, 2025

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Decreases By 46.4% - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Xenetic partners with PeriNess for cancer study in Israel By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Xenetic partners with PeriNess for cancer study in Israel - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma - standard-journal.com

Mar 26, 2025
pulisher
Mar 26, 2025

Breakthrough DNase Treatment Takes Aim at Aggressive Childhood Cancers in New Trial - Stock Titan

Mar 26, 2025
pulisher
Mar 24, 2025

Research Analysts Set Expectations for XBIO FY2025 Earnings - Defense World

Mar 24, 2025
pulisher
Mar 23, 2025

Xenetic Biosciences (NASDAQ:XBIO) Earns “Neutral” Rating from HC Wainwright - Defense World

Mar 23, 2025
pulisher
Mar 22, 2025

Analysts Offer Predictions for XBIO Q1 Earnings - Defense World

Mar 22, 2025
pulisher
Mar 19, 2025

Xenetic Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 19, 2025
pulisher
Mar 19, 2025

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results - Joplin Globe

Mar 19, 2025
pulisher
Mar 19, 2025

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Expands By 29.2% - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Xenetic Biosciences, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

XENETIC BIOSCIENCES Earnings Preview: Recent $XBIO Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025
pulisher
Mar 17, 2025

Xenetic Biosciences Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView

Mar 17, 2025
pulisher
Mar 13, 2025

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 07, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Armenian Reporter

Mar 07, 2025
pulisher
Mar 05, 2025

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire

Mar 02, 2025
pulisher
Feb 27, 2025

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard

Feb 27, 2025
pulisher
Feb 14, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Sees Large Decline in Short Interest - Armenian Reporter

Feb 14, 2025
pulisher
Feb 14, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World

Feb 14, 2025
pulisher
Feb 07, 2025

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire

Feb 07, 2025
pulisher
Jan 30, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World

Jan 30, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 22, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire

Jan 22, 2025
pulisher
Jan 21, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire

Jan 21, 2025
pulisher
Jan 16, 2025

XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 16, 2025
pulisher
Jan 13, 2025

XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com

Jan 13, 2025
pulisher
Jan 11, 2025

XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 11, 2025
pulisher
Dec 27, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World

Dec 27, 2024
pulisher
Dec 17, 2024

Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan

Dec 17, 2024
pulisher
Dec 16, 2024

Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan

Dec 16, 2024
pulisher
Dec 13, 2024

Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK

Dec 13, 2024
pulisher
Dec 06, 2024

Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada

Dec 06, 2024
pulisher
Dec 05, 2024

Xenetic and PeriNess partner for cancer treatment trials - Investing.com

Dec 05, 2024
pulisher
Dec 05, 2024

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire

Dec 05, 2024
pulisher
Dec 04, 2024

Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024
pulisher
Nov 30, 2024

Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 30, 2024
pulisher
Nov 29, 2024

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World

Nov 29, 2024

Xenetic Biosciences Inc (XBIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):